Table 3. Analytic results of the IL-17A rs2275913 polymorphism.

Genotype	G/G n = 11	G/A n = 86	A/A n = 18	p	OR [95% CI]
Mean onset age	39.27 ± 16.24	42.72 ± 14.11	36.44 ± 15.32	0.225	_
Mean DAS28	5.39 ± 1.37	5.87 ± 1.72	6.04 ± 1.66	0.923	_
DAS28 > 5,1 n (%)	7 (63.6%)	57 (66.3%)	15 (83.3%)	0.34	_
Subcutaneous nodules n(%)	1 (9.1%)	15 (17.6%)	7 (38.9%)a	0.029	3.22 [0.95–10.86]
Bone lesion n (%)	6 (54.5%)	40 (46.5%)	10 (55.6%)	0.721	_
Bone erosions n (%)	1 (9.1%)	27 (31.4%)	5 (27.8%)	0.13	_
Osteoporosis n (%)	5 (45.5%)b	13 (15.1%)	5 (27.8%)	0.041	3.98 [0.92–17.07]
ACCPA + n (%)	9 (81.8%)	61 (70.9%)	11 (61.1%)	0.485	_
Mean ACCPA level RU/ml	81.58	58.35	61.61	0.446	_
RF + n (%)	9 (81.8%)	56 (75.7%)	13 (72.2%)	0.843	_
RF > 100 IU/ml n (%)	8 (72.7%)	44 (60.3%)	11 (61.1%)	0.931	_
IgM-RF + n (%)	7 (63.6%)	51 (68.9%)	13 (72.2%)	0.889	_
Mean IgM-RF level IU/ml	150.91	114	165.94	0.482	_
IgA-RF + n (%)	8 (72.7%)	44 (59.5%)	9 (50%)	0.48	_
Mean IgM-RF level IU/ml	314.55	190.54	192.78	0.283	_
Plasma IL-17A level pg/ml	59.18	52.3	65.8	0.705	_

^a Chosen IL-17A genotype compared with the 2 other genotypes

^bChosen IL-17A genotype compared with the 2 other genotypes